HBW
CRSP icon

Hazlett, Burt & Watson’s CRISPR Therapeutics CRSP Stock Holding History

Hazlett, Burt & Watson’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
6
– – ﹤0.01% 920
2025
Q4 		$0 Hold
6
– – ﹤0.01% 921
2025
Q3 		$0 Hold
6
– – ﹤0.01% 875
2025
Q2 		$0 Hold
6
– – ﹤0.01% 801
2025
Q1 		$0 Hold
6
– – ﹤0.01% 793
2024
Q4 		$0 Hold
6
– – ﹤0.01% 758
2024
Q3 		$0 Hold
6
– – ﹤0.01% 725
2024
Q2 		$0 Hold
6
– – ﹤0.01% 702
2024
Q1 		$0 Hold
6
– – ﹤0.01% 704
2023
Q4 		$0 Sell
6
-82
-93% -$4.53K ﹤0.01% 691
2023
Q3 		$4K Buy
+88
New +$4.54K ﹤0.01% 581

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hazlett, Burt & Watson's CRSP Position: Q1 2026 in Review

Hazlett, Burt & Watson held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 6 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #920.

Hazlett, Burt & Watson first reported a position in CRSP in Q3 2023 and has held it in 11 quarters since. The position peaked at $4K in Q3 2023. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Hazlett, Burt & Watson held 6 shares of CRISPR Therapeutics worth $0 as of Q1 2026.
  • Hazlett, Burt & Watson left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Hazlett, Burt & Watson's portfolio in Q1 2026, its #920 holding.
  • Hazlett, Burt & Watson first reported a position in CRISPR Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Hazlett, Burt & Watson's CRISPR Therapeutics position peaked at $4K in Q3 2023.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q1 2026, filed 14 May 2026.